The utility of assessing C-peptide in patients with insulin-treated type 2 diabetes: a cross-sectional study.
Aged
Blood Glucose
/ drug effects
C-Peptide
/ analysis
Cross-Sectional Studies
Diabetes Mellitus, Type 2
/ blood
Drug Dosage Calculations
Female
Humans
Hypoglycemic Agents
/ therapeutic use
Insulin
/ administration & dosage
Insulin-Secreting Cells
/ drug effects
Male
Middle Aged
Predictive Value of Tests
Prognosis
Treatment Outcome
Beta cell
C-peptide
Insulin treatment
Type 2 diabetes
Journal
Acta diabetologica
ISSN: 1432-5233
Titre abrégé: Acta Diabetol
Pays: Germany
ID NLM: 9200299
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
09
09
2020
accepted:
04
11
2020
pubmed:
14
11
2020
medline:
5
6
2021
entrez:
13
11
2020
Statut:
ppublish
Résumé
We aimed at evaluating residual β-cell function in insulin-treated patients with type 2 diabetes (T2D) while determining for the first time the difference in C-peptide level between patients on basal-bolus compared to those on the basal insulin scheme, considered as an early stage of insulin treatment, together with assessing its correlation with the presence of complications. A total of 93 candidates with T2D were enrolled in this cross-sectional study and were categorized into two groups based on the insulin regimen: Basal-Bolus (BB) if on both basal and rapid acting insulin, and Basal (B) if on basal insulin only, without rapid acting injections. HbA1c, fasting C-peptide concentration and other metabolic parameters were recorded, as well as the patient medical history. The average fasting C-peptide was 1.81 ± 0.15 ng/mL, and its levels showed a significant inverse correlation with the duration of diabetes (r = -0.24, p = 0.03). Despite similar disease duration and metabolic control, BB participants displayed lower fasting C-peptide (p < 0.005) and higher fasting glucose (P = 0.01) compared with B patients. Concentrations below 1.09 ng/mL could predict the adoption of a basal-bolus treatment (Area 0.64, 95%CI:0.521-0.759, p = 0.038, sensitivity 45% and specificity 81%). Insulin-treated patients with long-standing T2D showed detectable level of fasting C-peptide. Measuring the β-cell function may therefore guide toward effective therapeutic options when oral hypoglycemic agents prove unsuccessful.
Identifiants
pubmed: 33185778
doi: 10.1007/s00592-020-01634-1
pii: 10.1007/s00592-020-01634-1
doi:
Substances chimiques
Blood Glucose
0
C-Peptide
0
Hypoglycemic Agents
0
Insulin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
411-417Références
World Health Organization. Health topics. Obesity. https://www.who.int/topics/obesity/en/ . https://www.who.int/topics/obesity/en/ . 2020
Watanabe M, Risi R, De Giorgi F et al (2020) Obesity treatment within the Italian national healthcare system tertiary care centers: what can we learn? Eat Weight Disord. https://doi.org/10.1007/s40519-020-00936-1
doi: 10.1007/s40519-020-00936-1
pubmed: 33150534
pmcid: 7453189
Hu FB (2011) Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care 34(6):1249–1257. https://doi.org/10.2337/dc11-0442
doi: 10.2337/dc11-0442
pubmed: 21617109
pmcid: 3114340
Basciani S, Camajani E, Contini S et al (2020) Very-low-calorie ketogenic diets with whey, vegetable or animal protein in patients with obesity: a randomized pilot study. J Clin Endocrinol Metab 105:336. https://doi.org/10.1210/clinem/dgaa336
doi: 10.1210/clinem/dgaa336
Basciani S, Costantini D, Contini S et al (2015) Safety and efficacy of a multiphase dietetic protocol with meal replacements including a step with very low calorie diet. Endocrine 48(3):863–870. https://doi.org/10.1007/s12020-014-0355-2
doi: 10.1007/s12020-014-0355-2
pubmed: 25063307
Bruci A, Tuccinardi D, Tozzi R et al (2020) Very low-calorie ketogenic diet: a safe and effective tool for weight loss in patients with obesity and mild kidney failure. Nutrients. https://doi.org/10.3390/nu12020333
doi: 10.3390/nu12020333
pubmed: 32012661
pmcid: 7071259
Soare A, Khazrai YM, Del Toro R et al (2014) The effect of the macrobiotic Ma-Pi 2 diet versus the recommended diet in the management of type 2 diabetes: the randomized controlled MADIAB trial. Nutr Metab (Lond). https://doi.org/10.1186/1743-7075-11-39
doi: 10.1186/1743-7075-11-39
Look ARG, Pi-Sunyer X, Blackburn G et al (2007) Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 30(6):1374–1383. https://doi.org/10.2337/dc07-0048
doi: 10.2337/dc07-0048
Watanabe M, Gangitano E, Francomano D et al (2018) Mangosteen extract shows a potent insulin sensitizing effect in obese female patients: a prospective randomized controlled pilot study. Nutrients. https://doi.org/10.3390/nu10050586
doi: 10.3390/nu10050586
pubmed: 30558355
pmcid: 6316252
Yilmaz Z, Piracha F, Anderson L, Mazzola N (2017) Supplements for diabetes mellitus: a review of the literature. J Pharm Pract 30(6):631–638. https://doi.org/10.1177/0897190016663070
doi: 10.1177/0897190016663070
pubmed: 27619931
Soare A, Del Toro R, Khazrai YM et al (2016) A 6-months follow-up study of the randomized controlled Ma–Pi macrobiotic dietary intervention (MADIAB trial) in type 2 diabetes. Nutr Diabetes 6(8):e222. https://doi.org/10.1038/nutd.2016.29
doi: 10.1038/nutd.2016.29
pubmed: 27525817
pmcid: 5022142
Watanabe M, Tuccinardi D, Ernesti I et al (2020) Scientific evidence underlying contraindications to the ketogenic diet: an update. Obes Rev. https://doi.org/10.1111/obr.13053
doi: 10.1111/obr.13053
pubmed: 32648647
pmcid: 7379247
Tuccinardi D, Farr OM, Upadhyay J et al (2019) Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: a six-month, randomized, placebo-controlled, double-blind clinical trial. Diabetes Obes Metab 21(6):1487–1492. https://doi.org/10.1111/dom.13655
doi: 10.1111/dom.13655
pubmed: 30724455
pmcid: 6504613
American Diabetes A (2019) 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes Care 42:S90–S102. https://doi.org/10.2337/dc19-S009
doi: 10.2337/dc19-S009
Bretzel RG, Eckhard M, Landgraf W, Owens DR, Linn T (2009) Initiating insulin therapy in type 2 diabetic patients failing on oral hypoglycemic agents: basal or prandial insulin? The APOLLO trial and beyond. Diabetes Care 32(Suppl 2):S260-265. https://doi.org/10.2337/dc09-S319
doi: 10.2337/dc09-S319
pubmed: 19875561
pmcid: 2811479
Centers for Disease Control and Prevention. National Diabetes Statistics Report (2020) Centers for disease control and prevention. US Department of Health and Human Services, Atlanta, GA
Swinnen SG, Hoekstra JB, DeVries JH (2009) Insulin therapy for type 2 diabetes. Diabetes Care 32(Suppl 2):S253-259. https://doi.org/10.2337/dc09-S318
doi: 10.2337/dc09-S318
pubmed: 19875560
pmcid: 2811456
Landin-Olsson M, Nilsson KO, Lernmark A, Sundkvist G (1990) Islet cell antibodies and fasting C-peptide predict insulin requirement at diagnosis of diabetes mellitus. Diabetologia 33(9):561–568. https://doi.org/10.1007/BF00404145
doi: 10.1007/BF00404145
pubmed: 2253834
American Diabetes A (2020) 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care 43:S14–S31. https://doi.org/10.2337/dc20-S002
doi: 10.2337/dc20-S002
Sabbah E, Savola K, Ebeling T et al (2000) Genetic, autoimmune, and clinical characteristics of childhood- and adult-onset type 1 diabetes. Diabetes Care 23(9):1326–1332. https://doi.org/10.2337/diacare.23.9.1326
doi: 10.2337/diacare.23.9.1326
pubmed: 10977027
Di Stasio E, Maggi D, Berardesca E et al (2011) Blue eyes as a risk factor for type 1 diabetes. Diabetes Metab Res Rev 27(6):609–613. https://doi.org/10.1002/dmrr.1214
doi: 10.1002/dmrr.1214
pubmed: 21557441
Shields BM, Peters JL, Cooper C et al (2015) Can clinical features be used to differentiate type 1 from type 2 diabetes? a systematic review of the literature. BMJ Open 5(11):e009088. https://doi.org/10.1136/bmjopen-2015-009088
doi: 10.1136/bmjopen-2015-009088
pubmed: 26525723
pmcid: 4636628
Jones AG, McDonald TJ, Shields BM et al (2016) Markers of beta-cell failure predict poor glycemic response to glp-1 receptor agonist therapy in type 2 diabetes. Diabetes Care 39(2):250–257. https://doi.org/10.2337/dc15-0258
doi: 10.2337/dc15-0258
pubmed: 26242184
Lee A, Morley J (1999) Classification of type 2 diabetes by clinical response to metformin-troglitazone combination and C-Peptide criteria. Endocr Pract 5(6):305–313. https://doi.org/10.4158/EP.5.6.305
doi: 10.4158/EP.5.6.305
pubmed: 15251651
Jones AG, Besser RE, Shields BM, McDonald TJ, Hope SV, Knight BA, Hattersley AT (2012) Assessment of endogenous insulin secretion in insulin treated diabetes predicts postprandial glucose and treatment response to prandial insulin. BMC Endocr Disord. https://doi.org/10.1186/1472-6823-12-6
doi: 10.1186/1472-6823-12-6
pubmed: 22681724
pmcid: 3405447
White MG, Shaw JA, Taylor R (2016) Type 2 diabetes: the pathologic basis of reversible beta-cell dysfunction. Diabetes Care 39(11):2080–2088. https://doi.org/10.2337/dc16-0619
doi: 10.2337/dc16-0619
pubmed: 27926891
Pieralice S, Pozzilli P (2018) Latent autoimmune diabetes in adults: a review on clinical implications and management. Diabetes Metab J 42(6):451–464. https://doi.org/10.4093/dmj.2018.0190
doi: 10.4093/dmj.2018.0190
pubmed: 30565440
pmcid: 6300440
Foley JE, Bunck MC, Moller-Goede DL et al (2011) Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. Diabetologia 54(8):1985–1991. https://doi.org/10.1007/s00125-011-2167-8
doi: 10.1007/s00125-011-2167-8
pubmed: 21547496
pmcid: 3131517
Chon S, Gautier JF (2016) An update on the effect of incretin-based therapies on beta-cell function and mass. Diabetes Metab J 40(2):99–114. https://doi.org/10.4093/dmj.2016.40.2.99
doi: 10.4093/dmj.2016.40.2.99
pubmed: 27126881
pmcid: 4853229
Kaneto H, Obata A, Kimura T et al (2017) Beneficial effects of sodium-glucose cotransporter 2 inhibitors for preservation of pancreatic beta-cell function and reduction of insulin resistance. J Diabetes 9(3):219–225. https://doi.org/10.1111/1753-0407.12494
doi: 10.1111/1753-0407.12494
pubmed: 27754601
Leighton E, Sainsbury CA, Jones GC (2017) A Practical review of C-peptide testing in diabetes. Diabetes Ther 8(3):475–487. https://doi.org/10.1007/s13300-017-0265-4
doi: 10.1007/s13300-017-0265-4
pubmed: 28484968
pmcid: 5446389
Alves MT, Ortiz MMO, Dos Reis G et al (2019) The dual effect of C-peptide on cellular activation and atherosclerosis: protective or not? Diabetes Metab Res Rev 35(1):e3071. https://doi.org/10.1002/dmrr.3071
doi: 10.1002/dmrr.3071
pubmed: 30160822
Covic AM, Schelling JR, Constantiner M, Iyengar SK, Sedor JR (2000) Serum C-peptide concentrations poorly phenotype type 2 diabetic end-stage renal disease patients. Kidney Int 58(4):1742–1750. https://doi.org/10.1046/j.1523-1755.2000.00335.x
doi: 10.1046/j.1523-1755.2000.00335.x
pubmed: 11012908
Haffner SM, Miettinen H, Stern MP (1997) Are risk factors for conversion to NIDDM similar in high and low risk populations? Diabetologia 40(1):62–66. https://doi.org/10.1007/s001250050643
doi: 10.1007/s001250050643
pubmed: 9028719